File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Nonaspirin nonsteroidal anti-inflammatory drugs and gastric cancer risk after Helicobacter pylori eradication: A territory-wide study

TitleNonaspirin nonsteroidal anti-inflammatory drugs and gastric cancer risk after Helicobacter pylori eradication: A territory-wide study
Authors
KeywordsHelicobacter pylori
chemoprevention
gastric cancer
immortal time bias
nonsteroidal anti-inflammatory drugs
Issue Date2021
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-0142
Citation
Cancer, 2021, v. 127 n. 11, p. 1805-1815 How to Cite?
AbstractBackground: Despite Helicobacter pylori (HP) eradication, individuals can still develop gastric cancer (GC). Prior studies have demonstrated that nonaspirin nonsteroidal anti-inflammatory drugs (NA-NSAIDs) reduce the risk of GC, but this may be caused by immortal time bias and failure to adjust for HP status. The objective of this study was to investigate whether NA-NSAIDs reduced the risk of GC in patients who undergo H. pylori eradication. Methods: Adult patients who had received clarithromycin-based triple therapy between 2003 and 2016 were identified from a territory-wide health care database. Exclusion criteria included prior GC or GC diagnosed <6 months after HP eradication, prior gastrectomy, gastric ulcer after HP eradication, and failure of triple therapy. Covariates included age, sex, prior peptic ulcer disease, other comorbidities, and concurrent medications (aspirin, proton pump inhibitors, statins, and metformin). To avoid immortal time bias, NA-NSAID use (≥90 days) was treated as a time-dependent variable in a multivariable Cox model (time-dependent analysis). Time-independent analysis was also performed. Results: During a median follow-up of 8.9 years (interquartile range, 5.4-12.6 years), 364 of 92,017 patients (0.4%) who underwent HP eradication developed GC. NA-NSAID use was associated with a significant reduction in the risk of GC in time-fixed analysis (adjusted hazard ratio [aHR], 0.65; 95% CI, 0.47-0.90), but not in time-dependent multivariable analysis (aHR, 1.35; 95% CI, 0.97-1.87). Time-dependent subgroup analyses also did not indicate any significant association between NA-NSAID use and either cardia GC (aHR, 0.75; 95% CI, 0.27-2.06) or noncardia GC (aHR, 1.28; 95% CI, 0.83-1.98). Conclusions: NA-NSAID use was not associated with a reduced risk of GC among patients who underwent HP eradication. The chemopreventive effect of NA-NSAIDs observed in prior studies may have been confounded by immortal time bias.
Persistent Identifierhttp://hdl.handle.net/10722/304304
ISSN
2021 Impact Factor: 6.921
2020 SCImago Journal Rankings: 3.052
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLi, B-
dc.contributor.authorCheung, KSM-
dc.contributor.authorWong, YHI-
dc.contributor.authorLeung, jWK-
dc.contributor.authorLaw, SYK-
dc.date.accessioned2021-09-23T08:58:09Z-
dc.date.available2021-09-23T08:58:09Z-
dc.date.issued2021-
dc.identifier.citationCancer, 2021, v. 127 n. 11, p. 1805-1815-
dc.identifier.issn0008-543X-
dc.identifier.urihttp://hdl.handle.net/10722/304304-
dc.description.abstractBackground: Despite Helicobacter pylori (HP) eradication, individuals can still develop gastric cancer (GC). Prior studies have demonstrated that nonaspirin nonsteroidal anti-inflammatory drugs (NA-NSAIDs) reduce the risk of GC, but this may be caused by immortal time bias and failure to adjust for HP status. The objective of this study was to investigate whether NA-NSAIDs reduced the risk of GC in patients who undergo H. pylori eradication. Methods: Adult patients who had received clarithromycin-based triple therapy between 2003 and 2016 were identified from a territory-wide health care database. Exclusion criteria included prior GC or GC diagnosed <6 months after HP eradication, prior gastrectomy, gastric ulcer after HP eradication, and failure of triple therapy. Covariates included age, sex, prior peptic ulcer disease, other comorbidities, and concurrent medications (aspirin, proton pump inhibitors, statins, and metformin). To avoid immortal time bias, NA-NSAID use (≥90 days) was treated as a time-dependent variable in a multivariable Cox model (time-dependent analysis). Time-independent analysis was also performed. Results: During a median follow-up of 8.9 years (interquartile range, 5.4-12.6 years), 364 of 92,017 patients (0.4%) who underwent HP eradication developed GC. NA-NSAID use was associated with a significant reduction in the risk of GC in time-fixed analysis (adjusted hazard ratio [aHR], 0.65; 95% CI, 0.47-0.90), but not in time-dependent multivariable analysis (aHR, 1.35; 95% CI, 0.97-1.87). Time-dependent subgroup analyses also did not indicate any significant association between NA-NSAID use and either cardia GC (aHR, 0.75; 95% CI, 0.27-2.06) or noncardia GC (aHR, 1.28; 95% CI, 0.83-1.98). Conclusions: NA-NSAID use was not associated with a reduced risk of GC among patients who underwent HP eradication. The chemopreventive effect of NA-NSAIDs observed in prior studies may have been confounded by immortal time bias.-
dc.languageeng-
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-0142-
dc.relation.ispartofCancer-
dc.subjectHelicobacter pylori-
dc.subjectchemoprevention-
dc.subjectgastric cancer-
dc.subjectimmortal time bias-
dc.subjectnonsteroidal anti-inflammatory drugs-
dc.titleNonaspirin nonsteroidal anti-inflammatory drugs and gastric cancer risk after Helicobacter pylori eradication: A territory-wide study-
dc.typeArticle-
dc.identifier.emailCheung, KSM: cks634@hku.hk-
dc.identifier.emailWong, YHI: iyhwong@hku.hk-
dc.identifier.emailLeung, jWK: waikleung@hku.hk-
dc.identifier.emailLaw, SYK: slaw@hku.hk-
dc.identifier.authorityCheung, KSM=rp02532-
dc.identifier.authorityWong, YHI=rp02293-
dc.identifier.authorityLeung, jWK=rp01479-
dc.identifier.authorityLaw, SYK=rp00437-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1002/cncr.33412-
dc.identifier.pmid33471380-
dc.identifier.hkuros325490-
dc.identifier.volume127-
dc.identifier.issue11-
dc.identifier.spage1805-
dc.identifier.epage1815-
dc.identifier.isiWOS:000608914000001-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats